Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Aura Biosciences, Inc. (AURA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, AURA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
What Makes Aura Biosciences (AURA) a New Buy Stock
Aura Biosciences (AURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)
Aura Biosciences, Inc (NASDAQ:AURA ) Virtual Urologic Oncology Investor Event Conference Call March 24, 2025 4:30 PM ET Company Participants Jill Hopkins - Chief Medical Officer & President of R&D Sabine Brookman-May - Senior Vice President, Therapeutic Area Head Urologic Oncology Joseph McQuaid - Clinical Lead, Urologic Oncology Jennifer Linehan - St. John's Cancer Institute Neal Shore - Carolina Urologic Research Center Gary Steinberg - Professor, Department of Urology at Rush University in Chicago Conference Call Participants Andy Berens - Leerink Philip Nadeau - TD Cowen Oliver McCammon - LifeSci Capital Jon Wolleben - JMP Securities George Farmer - Scotiabank Operator Good afternoon, and welcome to the Aura Biosciences Virtual Urologic Oncology Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Aura website following the conclusion of the event.
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).
